Related Experiment Video
Updated: Apr 23, 2026

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
ARV-based HIV prevention for women - where we are in 2014
Timothy D Mastro1, Nirupama Sista2, Quarraisha Abdool-Karim3
1FHI 360, Durham, North Carolina, USA; tmastro@fhi360.org.
Abstract:
Women continue to be at special risk for HIV acquisition due to a complex mix of biological, behavioural, structural, cultural and social factors, with unacceptable rates of new infection. Scientific advances over the past decade have highlighted the use of antiretroviral (ARV) drugs as pre-exposure prophylaxis (PrEP) to prevent HIV acquisition (sexually, parenterally and vertically) and ARV treatment (ART) for HIV-positive patients to prevent onward transmission (treatment as prevention - TasP). This paper reviews the evidence base for PrEP and TasP, describes new products in development and the need to translate research findings into programmes with impact at the population level.
Related Concept Videos
Sexually Transmitted Infections
Retrovirus Life Cycles
Cancer Prevention
Some...
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Preventive Healthcare Services
Models of Health Promotion and Illness Prevention II
The agent-host-environment model states that disease results...

